Articles from Tisento Therapeutics Inc

Tisento Therapeutics Announces Publication of MELAS Interview Study, Incorporating Patients’ Perspectives to Elucidate Symptoms and Impacts of Rare Mitochondrial Disease

Findings Demonstrate the Importance of Addressing Both Fatigue and Cognitive Symptoms of MELAS

By Tisento Therapeutics Inc · Via GlobeNewswire · November 3, 2025

First PRIZM Study Participant Enrolled in Tisento Therapeutics’ Open-Label Extension Study in MELAS

Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll

By Tisento Therapeutics Inc · Via GlobeNewswire · August 20, 2025

Tisento Therapeutics Receives U.S. FDA Fast Track Designation for Zagociguat for the Treatment of MELAS

Global Phase 2b PRIZM Study of Zagociguat is Currently Enrolling Participants with MELAS

By Tisento Therapeutics Inc · Via GlobeNewswire · June 17, 2025

Tisento Highlights Two Venues Advancing Patient-Focused Therapeutic Development for Mitochondrial Diseases

Tisento to Present at the “Primary Mitochondrial Diseases” Therapeutic Development Workshop Hosted by the Reagan-Udall Foundation for the FDA on May 22, 2025

By Tisento Therapeutics Inc · Via GlobeNewswire · May 14, 2025

First Participant Dosed in Tisento Therapeutics’ Global Phase 2b PRIZM Study Evaluating Zagociguat for the Treatment of MELAS

Patient-Centered PRIZM Study Measures Impact of Once-Daily Oral Zagociguat on Fatigue and Cognitive Impairment, Hallmark Features of this Rare Mitochondrial Disease

By Tisento Therapeutics Inc · Via GlobeNewswire · January 27, 2025

Tisento Therapeutics Initiates Interview Study with Individuals with MELAS to Elucidate the Symptoms and Impact of Disease and Inform the Zagociguat Clinical Development Program

– Interviews Intended to Illuminate Experience of Living with MELAS, a Rare Mitochondrial Disease –

By Tisento Therapeutics Inc · Via GlobeNewswire · October 25, 2023